In a fresh news release, Nuwellis (NASDAQ:NUWE) announced encouraging clinical data related to proprietary technology that could be deployed in cardiac surgery. The results were released in the Journal of Cardiac Surgery, and it is potentially good news for cardiac patients. At the very least, it’s having a positive impact on NUWE stock today.
Nuwellis studied their Aquadex FlexFlow System, not during surgeries, but in selected postoperative coronary artery bypass grafting patients. The company states, “Excess fluid overload in the perioperative phase of care has been associated with increased morbidity and mortality” for postoperative coronary artery bypass grafting (CABG) patients.
Clearly, this study could have been make-or-break for a small company like Nuwellis. Thankfully, the results were positive. In fact, they demonstrated a perfect, 100% 30-day survival rate for tested patients who were treated with ultrafiltration.
This post originally appeared at InvestorPlace.